Kynmobi

Apomorphine hydrochloride, the active ingredient in Kynmobi, is a dopamine agonist presented as a sublingual tablet for sublingual use. It restores dopaminergic stimulation during OFF episodes in Parkinson's disease. GNH USA supplies Kynmobi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kynmobi, a dopamine agonist, acts on the dopaminergic pathway to manage motor fluctuations in Parkinson's disease. - Parkinson's disease (OFF episodes): Reduces the frequency and duration of OFF periods. - Parkinson's disease (early morning OFF): Improves motor function upon waking. - Parkinson's disease (motor fluctuations): Enhances overall motor performance during fluctuations.

Common Side Effects: - Nausea and vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Somnolence or fatigue - Dry mouth Serious or Rare Side Effects: - Severe hypotension or syncope - Hallucinations or psychosis - Impulse control disorders - Severe nausea or persistent vomiting - Cardiac arrhythmias - Allergic reactions such as rash or angioedema

Patients should be monitored closely when initiating therapy. - Dose titration: Start with a low dose and increase gradually under medical supervision. - Cardiovascular monitoring: Observe for hypotension and syncope, especially after the first dose. - Neuropsychiatric assessment: Watch for hallucinations, confusion, or impulse control changes. - Contraindications: Avoid in individuals with known hypersensitivity to apomorphine or its excipients. - Pregnancy and lactation: Safety not established; use only if benefits outweigh potential risks. - Store at ambient temperature: Keep in the original container, protect from moisture and heat.

Apomorphine may interact with several drug classes. Major Interactions (Avoid): - MAO inhibitors: Risk of hypertensive crisis. - Antiemetics such as metoclopramide or domperidone: Antagonize dopaminergic effect. - Antipsychotics (e.g., haloperidol, risperidone): Block dopamine receptors, reducing efficacy. Moderate Interactions (Monitor Closely): - Antihypertensives: Additive hypotensive effect. - SSRIs or SNRIs: May increase risk of serotonin syndrome. - Alcohol: Can enhance central nervous system depression.